Hosted on MSN

Compass Pathways gains after FDA clears IND for PTSD trial of COMP360

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy

Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...
Business Wire

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
Seeking Alpha

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression - Slideshow

The following slide deck was published by COMPASS Pathways plc in conjunction with this event.